… resulted in synergistically enhanced cytotoxicity compared to pitavastatin monotherapy. …
All cell lines studied in this work were erlotinib resistant and EGFR wild type (Table 1). Cells …

… Erlotinib, the epidermal growth factor receptor (EGFR)-targeting tyrosine … cell lung cancer
where it seems to be more effective in patients with EGFR mutations. Resistance to erlotinib is a …

… following study subpopulations: nonselected monotherapy first line, maintenance or
consolidation with either gefitinib or erlotinib in first line, monotherapy second line, mutation positive …

… in survival in pancreatic cancer by adding a second … of erlotinib for the treatment of pancreatic
cancer in the United States. Furthermore, in a phase III trial (BR.21), erlotinib monotherapy …

… -carboplatin plus erlotinib administered orally at 150 mg/dL per day beginning on the first
day of the third cycle and continued with erlotinib monotherapy thereafter until progression. …

… Our meta-analysis indicates that compared with monotherapy, erlotinib+bevacizumab
combination therapy prolongs PFS of patients with NSCLC, but cannot extend OS or elevate ORR. …

… (TKI) has proved effective for selective advanced lung cancer patients in Taiwan. We …
stage IIIb or IV non-squamous cell, non-small cell lung cancer (NSqCLC) who responded to …

… erlotinib and an angiogenesis inhibitor significantly prolonged PFS compared with erlotinib
monotherapy in … The RELAY study found that the combination of erlotinib and ramucirumab, a …

… efficacy and safety of erlotinib for non-small cell lung cancer (NSCLC), … erlotinib at 14 sites
(17 departments) in Ibaraki (Japan) between December 2007 and December 2010. The tumor …

… The TRUST study was an open-label, phase IV study with erlotinib monotherapy in
patients with advanced NSCLC who had previously progressed after at least one previous …